Hung V. Ngo

Array ( [id] => 8222019 [patent_doc_number] => 20120136220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-31 [patent_title] => 'COMPOSITIONS AND METHODS FOR ENHANCING BRAIN FUNCTION' [patent_app_type] => utility [patent_app_number] => 13/307587 [patent_app_country] => US [patent_app_date] => 2011-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9838 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13307587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9922978 [patent_doc_number] => 08980940 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-17 [patent_title] => 'Stable cannabinoid compositions and methods for making and storing them' [patent_app_type] => utility [patent_app_number] => 13/302289 [patent_app_country] => US [patent_app_date] => 2011-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15208 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13302289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8265930 [patent_doc_number] => 20120165358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-28 [patent_title] => 'CONTROLLED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS' [patent_app_type] => utility [patent_app_number] => 13/300380 [patent_app_country] => US [patent_app_date] => 2011-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 48235 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13300380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9944330 [patent_doc_number] => 08993631 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-31 [patent_title] => 'Method of treating contrast-induced nephropathy' [patent_app_type] => utility [patent_app_number] => 13/294295 [patent_app_country] => US [patent_app_date] => 2011-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76467 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13294295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8186915 [patent_doc_number] => 20120115939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-10 [patent_title] => 'METHODS FOR USING LIPOIC ACID' [patent_app_type] => utility [patent_app_number] => 13/292525 [patent_app_country] => US [patent_app_date] => 2011-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 5214 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0115/20120115939.pdf [firstpage_image] =>[orig_patent_app_number] => 13292525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9161080 [patent_doc_number] => 20130309357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-21 [patent_title] => 'PET FOOD PREPARATIONS CONTAINING PROBIOTIC MICRO-ORGANISMS' [patent_app_type] => utility [patent_app_number] => 13/881492 [patent_app_country] => US [patent_app_date] => 2011-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 9489 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13881492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9710857 [patent_doc_number] => 08835425 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-09-16 [patent_title] => 'Use of selective GABA A α5 negative allosteric modulators for the treatment of central nervous system conditions' [patent_app_type] => utility [patent_app_number] => 13/286240 [patent_app_country] => US [patent_app_date] => 2011-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 21106 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13286240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8405488 [patent_doc_number] => 20120237551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS' [patent_app_type] => utility [patent_app_number] => 13/279696 [patent_app_country] => US [patent_app_date] => 2011-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7233 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13279696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9004478 [patent_doc_number] => 20130225603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-29 [patent_title] => 'MDM2 INHIBITORS FOR TREATMENT OF OCULAR CONDITIONS' [patent_app_type] => utility [patent_app_number] => 13/876408 [patent_app_country] => US [patent_app_date] => 2011-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 22802 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13876408 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7720944 [patent_doc_number] => 20120010279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-12 [patent_title] => 'COMPOSITION COMPRISING (-)-DELTA9-TRANS-TETRAHYDROCANNABINOL' [patent_app_type] => utility [patent_app_number] => 13/237388 [patent_app_country] => US [patent_app_date] => 2011-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3417 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0010/20120010279.pdf [firstpage_image] =>[orig_patent_app_number] => 13237388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8313682 [patent_doc_number] => 20120190702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-26 [patent_title] => 'USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS' [patent_app_type] => utility [patent_app_number] => 13/230193 [patent_app_country] => US [patent_app_date] => 2011-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8352 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13230193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7791643 [patent_doc_number] => 20120053199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-01 [patent_title] => 'NOSCAPINE AND ANALOGS AND METHODS RELATED THERETO' [patent_app_type] => utility [patent_app_number] => 13/216458 [patent_app_country] => US [patent_app_date] => 2011-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 15082 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0053/20120053199.pdf [firstpage_image] =>[orig_patent_app_number] => 13216458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7663659 [patent_doc_number] => 20110312928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-22 [patent_title] => 'Progesterone Containing Oral Dosage Forms and Related Methods' [patent_app_type] => utility [patent_app_number] => 13/204562 [patent_app_country] => US [patent_app_date] => 2011-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 16395 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0312/20110312928.pdf [firstpage_image] =>[orig_patent_app_number] => 13204562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7567474 [patent_doc_number] => 20110287537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-24 [patent_title] => 'NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES' [patent_app_type] => utility [patent_app_number] => 13/195626 [patent_app_country] => US [patent_app_date] => 2011-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 12323 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0287/20110287537.pdf [firstpage_image] =>[orig_patent_app_number] => 13195626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10095841 [patent_doc_number] => 09132136 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-15 [patent_title] => 'Pharmaceutical combination' [patent_app_type] => utility [patent_app_number] => 13/189600 [patent_app_country] => US [patent_app_date] => 2011-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 25 [patent_no_of_words] => 15941 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13189600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8363263 [patent_doc_number] => 08252327 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-08-28 [patent_title] => 'Oral controlled release dosage form' [patent_app_type] => utility [patent_app_number] => 13/179830 [patent_app_country] => US [patent_app_date] => 2011-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6029 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 360 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13179830 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7720894 [patent_doc_number] => 20120010229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-12 [patent_title] => 'THERAPEUTIC REGIMENS FOR HEDGEHOG-ASSOCIATED CANCERS' [patent_app_type] => utility [patent_app_number] => 13/179404 [patent_app_country] => US [patent_app_date] => 2011-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 42158 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0010/20120010229.pdf [firstpage_image] =>[orig_patent_app_number] => 13179404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8822320 [patent_doc_number] => 20130123365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-16 [patent_title] => 'USE OF FTS AND ANALOGS TO TREAT NON-AUTOIMMUNE-ALLERGIC AND NON-ALLERGIC INFLAMMATORY CONDITIONS' [patent_app_type] => utility [patent_app_number] => 13/809044 [patent_app_country] => US [patent_app_date] => 2011-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5920 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13809044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7744528 [patent_doc_number] => 20120022095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-26 [patent_title] => 'TOPICAL RAPAMYCIN FOR TREATMENT OF FACIAL ANGIOFIBROMAS IN TUBEROUS SCLEROSIS' [patent_app_type] => utility [patent_app_number] => 13/168634 [patent_app_country] => US [patent_app_date] => 2011-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 2242 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0022/20120022095.pdf [firstpage_image] =>[orig_patent_app_number] => 13168634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7670185 [patent_doc_number] => 20110319454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-29 [patent_title] => 'DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY' [patent_app_type] => utility [patent_app_number] => 13/168464 [patent_app_country] => US [patent_app_date] => 2011-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16437 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13168464 [rel_patent_id] =>[rel_patent_doc_number] =>)